The European authority adopted positive opinion for new combination as first line treatment for stage IV metastatic lung cancer
About Non Small Cell Lung Cancer, NSCLC Lung cancer is the leading cause of cancer death globally. Each year 1.76 million people die as a
New hope for ovarian cancer patients – regardless of BRCA status
Background – The first standard treatment for advanced ovarian cancer patients is platinum-based chemotherapy. If the patient responds to this chemotherapy, she will continue to
Not only for MSI-H! A combination of two approved drugs is in Phase III trial for MSS colorectal cancer
Background – The combination of regorafenib (Stivarga) and nivolumab (Opdivo) will be compared with regorafenib alone in a phase III trial of patients with microsatellite
Is an immunotherapy approved drug on its way to treat Small Cell Lung Cancer, SCLC?
About Orphan Drug and the “CASPIAN” – The FDA has granted an orphan drug designation to “Durvalumab” (“Imfinzi”) for the treatment of patients with small
We Are Proud To Be At the Forefront of Personalized Medicine to Update You on This Novel Cancer Drug Approval
About the approval, the studies and the drug, entrectinib – The first regulatory approval has been granted to entrectinib (Rozlytrek) in Japan for the treatment
Significant prolongation of life in patients with metastatic colorectal cancer with new treatment
The study and treatment At the World Congress on Gastrointestinal Cancer, held in Barcelona, Spain, on July 3-6, 2019, updated results from a study of
Keytruda Prolongs Life as First Line Treatment for Advanced Head & Neck Cancer
The best management for any patient with cancer is receiving the most innovative cancer drugs in advanced stages of development. There, the hope and chances
A breakthrough in cancer research: A drug for young people proved effective and prolongs life
A new drug called Entrectinib for the treatment of children and adults with cancer that has recurred or is resistant to treatment, including brain cancers
An Approved Cancer Drug for Breast Cancer Is Now a Potential New Treatment Option for HER2-Amplified Advanced Salivary Gland Cancer
About “Kadcyla”, Ado-trastuzumab emtansine and HER2-Amplified Advanced Salivary Gland Cancer, SGC – Ado-trastuzumab emtansine, more commonly known as T-DM1 and sold under the trade name “Kadcyla”,
Promising progress in the treatment of neuroblastoma, a common type of cancer among children
Background Researchers from Baylor College of Medicine published preliminary findings on the first two patients treated in a Phase I clinical trial, first of its
Innovative brain cancer drug for non-treatable DIPG
Published on May 9, 2019 Researchers at the Cancer Research Institute in London, England, led an international drug development team that can treat DIPG, Diffuse
FDA Expands Keytruda® Approval for Front Line Treatment of NSCLC
On April 14, 2019, the FDA approved Keytruda® as first line monotherapy for non-small cell lung, NSCLC, cancer patients whose cancer cells express PD-L1 and
